nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—Embolism venous—Doxorubicin—muscle cancer	0.0107	0.0109	CcSEcCtD
Lurasidone—Lethargy—Dactinomycin—muscle cancer	0.0106	0.0108	CcSEcCtD
Lurasidone—Deep vein thrombosis—Methotrexate—muscle cancer	0.0102	0.0104	CcSEcCtD
Lurasidone—Dysphagia—Dactinomycin—muscle cancer	0.00898	0.00917	CcSEcCtD
Lurasidone—Serum creatinine increased—Doxorubicin—muscle cancer	0.00874	0.00892	CcSEcCtD
Lurasidone—Neutropenia—Dactinomycin—muscle cancer	0.0084	0.00857	CcSEcCtD
Lurasidone—Hypokinesia—Doxorubicin—muscle cancer	0.00796	0.00812	CcSEcCtD
Lurasidone—Dysuria—Vincristine—muscle cancer	0.00751	0.00766	CcSEcCtD
Lurasidone—Neutropenia—Vincristine—muscle cancer	0.00751	0.00766	CcSEcCtD
Lurasidone—Agranulocytosis—Dactinomycin—muscle cancer	0.00748	0.00763	CcSEcCtD
Lurasidone—Erectile dysfunction—Vincristine—muscle cancer	0.00739	0.00754	CcSEcCtD
Lurasidone—Musculoskeletal stiffness—Methotrexate—muscle cancer	0.00692	0.00706	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Etoposide—muscle cancer	0.00664	0.00677	CcSEcCtD
Lurasidone—Dysarthria—Methotrexate—muscle cancer	0.00656	0.0067	CcSEcCtD
Lurasidone—Dysphagia—Etoposide—muscle cancer	0.0065	0.00663	CcSEcCtD
Lurasidone—Urinary tract disorder—Vincristine—muscle cancer	0.00634	0.00647	CcSEcCtD
Lurasidone—Connective tissue disorder—Vincristine—muscle cancer	0.00631	0.00644	CcSEcCtD
Lurasidone—Urethral disorder—Vincristine—muscle cancer	0.0063	0.00643	CcSEcCtD
Lurasidone—Pulmonary embolism—Methotrexate—muscle cancer	0.00621	0.00633	CcSEcCtD
Lurasidone—Breast pain—Doxorubicin—muscle cancer	0.00616	0.00629	CcSEcCtD
Lurasidone—Cardiovascular disorder—Doxorubicin—muscle cancer	0.00612	0.00624	CcSEcCtD
Lurasidone—Amenorrhoea—Doxorubicin—muscle cancer	0.00612	0.00624	CcSEcCtD
Lurasidone—Neutropenia—Etoposide—muscle cancer	0.00608	0.0062	CcSEcCtD
Lurasidone—Cardiac disorder—Vincristine—muscle cancer	0.00596	0.00608	CcSEcCtD
Lurasidone—Angiopathy—Vincristine—muscle cancer	0.00583	0.00595	CcSEcCtD
Lurasidone—Infestation NOS—Etoposide—muscle cancer	0.0058	0.00592	CcSEcCtD
Lurasidone—Infestation—Etoposide—muscle cancer	0.0058	0.00592	CcSEcCtD
Lurasidone—Anaemia—Dactinomycin—muscle cancer	0.00579	0.0059	CcSEcCtD
Lurasidone—Dyskinesia—Doxorubicin—muscle cancer	0.00572	0.00584	CcSEcCtD
Lurasidone—Renal failure—Etoposide—muscle cancer	0.0057	0.00582	CcSEcCtD
Lurasidone—Dysarthria—Doxorubicin—muscle cancer	0.00568	0.0058	CcSEcCtD
Lurasidone—Creatinine increased—Doxorubicin—muscle cancer	0.00565	0.00576	CcSEcCtD
Lurasidone—Malaise—Dactinomycin—muscle cancer	0.00565	0.00576	CcSEcCtD
Lurasidone—Mental disorder—Vincristine—muscle cancer	0.00563	0.00574	CcSEcCtD
Lurasidone—Leukopenia—Dactinomycin—muscle cancer	0.0056	0.00572	CcSEcCtD
Lurasidone—Atrioventricular block—Doxorubicin—muscle cancer	0.00554	0.00565	CcSEcCtD
Lurasidone—Gait disturbance—Doxorubicin—muscle cancer	0.00551	0.00562	CcSEcCtD
Lurasidone—Hepatobiliary disease—Etoposide—muscle cancer	0.00548	0.00559	CcSEcCtD
Lurasidone—Neck pain—Doxorubicin—muscle cancer	0.00544	0.00555	CcSEcCtD
Lurasidone—Agranulocytosis—Etoposide—muscle cancer	0.00541	0.00552	CcSEcCtD
Lurasidone—Back pain—Vincristine—muscle cancer	0.00541	0.00552	CcSEcCtD
Lurasidone—Pulmonary embolism—Doxorubicin—muscle cancer	0.00538	0.00549	CcSEcCtD
Lurasidone—Myalgia—Dactinomycin—muscle cancer	0.00533	0.00544	CcSEcCtD
Lurasidone—Abnormal dreams—Doxorubicin—muscle cancer	0.00531	0.00542	CcSEcCtD
Lurasidone—Salivary hypersecretion—Doxorubicin—muscle cancer	0.00522	0.00533	CcSEcCtD
Lurasidone—Diabetes mellitus—Methotrexate—muscle cancer	0.00518	0.00529	CcSEcCtD
Lurasidone—Anaemia—Vincristine—muscle cancer	0.00517	0.00527	CcSEcCtD
Lurasidone—Urinary tract disorder—Etoposide—muscle cancer	0.00514	0.00524	CcSEcCtD
Lurasidone—Agitation—Vincristine—muscle cancer	0.00514	0.00524	CcSEcCtD
Lurasidone—Urethral disorder—Etoposide—muscle cancer	0.0051	0.00521	CcSEcCtD
Lurasidone—Infection—Dactinomycin—muscle cancer	0.00508	0.00518	CcSEcCtD
Lurasidone—Vertigo—Vincristine—muscle cancer	0.00502	0.00513	CcSEcCtD
Lurasidone—Leukopenia—Vincristine—muscle cancer	0.00501	0.00511	CcSEcCtD
Lurasidone—Eye disorder—Etoposide—muscle cancer	0.00486	0.00496	CcSEcCtD
Lurasidone—Convulsion—Vincristine—muscle cancer	0.00485	0.00494	CcSEcCtD
Lurasidone—Cardiac disorder—Etoposide—muscle cancer	0.00483	0.00493	CcSEcCtD
Lurasidone—Hypertension—Vincristine—muscle cancer	0.00483	0.00493	CcSEcCtD
Lurasidone—Myalgia—Vincristine—muscle cancer	0.00476	0.00486	CcSEcCtD
Lurasidone—Angiopathy—Etoposide—muscle cancer	0.00472	0.00482	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00465	0.00475	CcSEcCtD
Lurasidone—Cerebrovascular accident—Methotrexate—muscle cancer	0.0046	0.00469	CcSEcCtD
Lurasidone—Lethargy—Methotrexate—muscle cancer	0.0046	0.00469	CcSEcCtD
Lurasidone—Infection—Vincristine—muscle cancer	0.00453	0.00463	CcSEcCtD
Lurasidone—Osteoarthritis—Methotrexate—muscle cancer	0.00451	0.0046	CcSEcCtD
Lurasidone—Diabetes mellitus—Doxorubicin—muscle cancer	0.00449	0.00458	CcSEcCtD
Lurasidone—Nervous system disorder—Vincristine—muscle cancer	0.00448	0.00457	CcSEcCtD
Lurasidone—Decreased appetite—Dactinomycin—muscle cancer	0.00444	0.00453	CcSEcCtD
Lurasidone—Hyperhidrosis—Vincristine—muscle cancer	0.00441	0.0045	CcSEcCtD
Lurasidone—Fatigue—Dactinomycin—muscle cancer	0.0044	0.00449	CcSEcCtD
Lurasidone—Back pain—Etoposide—muscle cancer	0.00438	0.00447	CcSEcCtD
Lurasidone—Muscle spasms—Etoposide—muscle cancer	0.00436	0.00444	CcSEcCtD
Lurasidone—Hypotension—Vincristine—muscle cancer	0.00427	0.00435	CcSEcCtD
Lurasidone—Anaemia—Etoposide—muscle cancer	0.00419	0.00427	CcSEcCtD
Lurasidone—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00418	0.00426	CcSEcCtD
Lurasidone—Hot flush—Doxorubicin—muscle cancer	0.00417	0.00426	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00416	0.00424	CcSEcCtD
Lurasidone—Increased appetite—Doxorubicin—muscle cancer	0.00415	0.00424	CcSEcCtD
Lurasidone—Menopausal symptoms—Doxorubicin—muscle cancer	0.00414	0.00422	CcSEcCtD
Lurasidone—Insomnia—Vincristine—muscle cancer	0.00413	0.00421	CcSEcCtD
Lurasidone—Malaise—Etoposide—muscle cancer	0.00409	0.00417	CcSEcCtD
Lurasidone—Breast disorder—Methotrexate—muscle cancer	0.00407	0.00416	CcSEcCtD
Lurasidone—Vertigo—Etoposide—muscle cancer	0.00407	0.00415	CcSEcCtD
Lurasidone—Leukopenia—Etoposide—muscle cancer	0.00406	0.00414	CcSEcCtD
Lurasidone—Abdominal pain—Dactinomycin—muscle cancer	0.00404	0.00412	CcSEcCtD
Lurasidone—Loss of consciousness—Etoposide—muscle cancer	0.00398	0.00406	CcSEcCtD
Lurasidone—Cerebrovascular accident—Doxorubicin—muscle cancer	0.00398	0.00406	CcSEcCtD
Lurasidone—Lethargy—Doxorubicin—muscle cancer	0.00398	0.00406	CcSEcCtD
Lurasidone—Decreased appetite—Vincristine—muscle cancer	0.00397	0.00405	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Vincristine—muscle cancer	0.00394	0.00402	CcSEcCtD
Lurasidone—Fatigue—Vincristine—muscle cancer	0.00394	0.00402	CcSEcCtD
Lurasidone—Convulsion—Etoposide—muscle cancer	0.00393	0.00401	CcSEcCtD
Lurasidone—Hypertension—Etoposide—muscle cancer	0.00391	0.00399	CcSEcCtD
Lurasidone—Osteoarthritis—Doxorubicin—muscle cancer	0.0039	0.00398	CcSEcCtD
Lurasidone—Eosinophilia—Methotrexate—muscle cancer	0.00386	0.00393	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00383	0.00391	CcSEcCtD
Lurasidone—Abdominal discomfort—Methotrexate—muscle cancer	0.00373	0.00381	CcSEcCtD
Lurasidone—Gastrointestinal pain—Vincristine—muscle cancer	0.00373	0.00381	CcSEcCtD
Lurasidone—Infection—Etoposide—muscle cancer	0.00367	0.00375	CcSEcCtD
Lurasidone—Asthenia—Dactinomycin—muscle cancer	0.00367	0.00374	CcSEcCtD
Lurasidone—Blood creatinine increased—Doxorubicin—muscle cancer	0.00366	0.00373	CcSEcCtD
Lurasidone—Dysuria—Methotrexate—muscle cancer	0.00364	0.00372	CcSEcCtD
Lurasidone—Neutropenia—Methotrexate—muscle cancer	0.00364	0.00372	CcSEcCtD
Lurasidone—Tachycardia—Etoposide—muscle cancer	0.00361	0.00368	CcSEcCtD
Lurasidone—Abdominal pain—Vincristine—muscle cancer	0.00361	0.00368	CcSEcCtD
Lurasidone—Skin disorder—Etoposide—muscle cancer	0.00359	0.00366	CcSEcCtD
Lurasidone—Erectile dysfunction—Methotrexate—muscle cancer	0.00359	0.00366	CcSEcCtD
Lurasidone—Hyperhidrosis—Etoposide—muscle cancer	0.00357	0.00365	CcSEcCtD
Lurasidone—Abdominal pain upper—Doxorubicin—muscle cancer	0.00356	0.00364	CcSEcCtD
Lurasidone—Orthostatic hypotension—Doxorubicin—muscle cancer	0.00356	0.00364	CcSEcCtD
Lurasidone—Breast disorder—Doxorubicin—muscle cancer	0.00353	0.0036	CcSEcCtD
Lurasidone—Diarrhoea—Dactinomycin—muscle cancer	0.0035	0.00357	CcSEcCtD
Lurasidone—Nasopharyngitis—Doxorubicin—muscle cancer	0.00349	0.00356	CcSEcCtD
Lurasidone—Infestation NOS—Methotrexate—muscle cancer	0.00347	0.00354	CcSEcCtD
Lurasidone—Infestation—Methotrexate—muscle cancer	0.00347	0.00354	CcSEcCtD
Lurasidone—Hypotension—Etoposide—muscle cancer	0.00346	0.00353	CcSEcCtD
Lurasidone—Gastritis—Doxorubicin—muscle cancer	0.00345	0.00352	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.00344	0.00351	CcSEcCtD
Lurasidone—Renal failure—Methotrexate—muscle cancer	0.00341	0.00348	CcSEcCtD
Lurasidone—Dysphagia—Doxorubicin—muscle cancer	0.00337	0.00344	CcSEcCtD
Lurasidone—Influenza—Doxorubicin—muscle cancer	0.00337	0.00344	CcSEcCtD
Lurasidone—Eosinophilia—Doxorubicin—muscle cancer	0.00334	0.00341	CcSEcCtD
Lurasidone—Dyspnoea—Etoposide—muscle cancer	0.0033	0.00336	CcSEcCtD
Lurasidone—Somnolence—Etoposide—muscle cancer	0.00329	0.00335	CcSEcCtD
Lurasidone—Angina pectoris—Doxorubicin—muscle cancer	0.00329	0.00335	CcSEcCtD
Lurasidone—Hepatobiliary disease—Methotrexate—muscle cancer	0.00328	0.00335	CcSEcCtD
Lurasidone—Asthenia—Vincristine—muscle cancer	0.00327	0.00334	CcSEcCtD
Lurasidone—Vomiting—Dactinomycin—muscle cancer	0.00325	0.00331	CcSEcCtD
Lurasidone—Agranulocytosis—Methotrexate—muscle cancer	0.00324	0.00331	CcSEcCtD
Lurasidone—Rash—Dactinomycin—muscle cancer	0.00322	0.00329	CcSEcCtD
Lurasidone—Decreased appetite—Etoposide—muscle cancer	0.00321	0.00328	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Etoposide—muscle cancer	0.00319	0.00326	CcSEcCtD
Lurasidone—Fatigue—Etoposide—muscle cancer	0.00319	0.00325	CcSEcCtD
Lurasidone—Dysuria—Doxorubicin—muscle cancer	0.00315	0.00322	CcSEcCtD
Lurasidone—Neutropenia—Doxorubicin—muscle cancer	0.00315	0.00322	CcSEcCtD
Lurasidone—Diarrhoea—Vincristine—muscle cancer	0.00312	0.00319	CcSEcCtD
Lurasidone—Urinary tract disorder—Methotrexate—muscle cancer	0.00308	0.00314	CcSEcCtD
Lurasidone—Weight increased—Doxorubicin—muscle cancer	0.00307	0.00313	CcSEcCtD
Lurasidone—Urethral disorder—Methotrexate—muscle cancer	0.00306	0.00312	CcSEcCtD
Lurasidone—Hyperglycaemia—Doxorubicin—muscle cancer	0.00304	0.0031	CcSEcCtD
Lurasidone—Nausea—Dactinomycin—muscle cancer	0.00303	0.0031	CcSEcCtD
Lurasidone—Gastrointestinal pain—Etoposide—muscle cancer	0.00302	0.00309	CcSEcCtD
Lurasidone—Dizziness—Vincristine—muscle cancer	0.00302	0.00308	CcSEcCtD
Lurasidone—Infestation NOS—Doxorubicin—muscle cancer	0.00301	0.00307	CcSEcCtD
Lurasidone—Infestation—Doxorubicin—muscle cancer	0.00301	0.00307	CcSEcCtD
Lurasidone—Renal failure—Doxorubicin—muscle cancer	0.00296	0.00302	CcSEcCtD
Lurasidone—Abdominal pain—Etoposide—muscle cancer	0.00292	0.00298	CcSEcCtD
Lurasidone—Urinary tract infection—Doxorubicin—muscle cancer	0.00292	0.00298	CcSEcCtD
Lurasidone—Eye disorder—Methotrexate—muscle cancer	0.00291	0.00297	CcSEcCtD
Lurasidone—Vomiting—Vincristine—muscle cancer	0.0029	0.00296	CcSEcCtD
Lurasidone—Cardiac disorder—Methotrexate—muscle cancer	0.00289	0.00295	CcSEcCtD
Lurasidone—Rash—Vincristine—muscle cancer	0.00288	0.00294	CcSEcCtD
Lurasidone—Dermatitis—Vincristine—muscle cancer	0.00288	0.00293	CcSEcCtD
Lurasidone—Hepatobiliary disease—Doxorubicin—muscle cancer	0.00284	0.0029	CcSEcCtD
Lurasidone—Angiopathy—Methotrexate—muscle cancer	0.00283	0.00289	CcSEcCtD
Lurasidone—Agranulocytosis—Doxorubicin—muscle cancer	0.00281	0.00286	CcSEcCtD
Lurasidone—Bradycardia—Doxorubicin—muscle cancer	0.00275	0.0028	CcSEcCtD
Lurasidone—Mental disorder—Methotrexate—muscle cancer	0.00273	0.00279	CcSEcCtD
Lurasidone—Malnutrition—Methotrexate—muscle cancer	0.00271	0.00277	CcSEcCtD
Lurasidone—Nausea—Vincristine—muscle cancer	0.00271	0.00277	CcSEcCtD
Lurasidone—Urinary tract disorder—Doxorubicin—muscle cancer	0.00267	0.00272	CcSEcCtD
Lurasidone—Asthenia—Etoposide—muscle cancer	0.00265	0.00271	CcSEcCtD
Lurasidone—Connective tissue disorder—Doxorubicin—muscle cancer	0.00265	0.00271	CcSEcCtD
Lurasidone—Urethral disorder—Doxorubicin—muscle cancer	0.00265	0.0027	CcSEcCtD
Lurasidone—Back pain—Methotrexate—muscle cancer	0.00262	0.00268	CcSEcCtD
Lurasidone—Pruritus—Etoposide—muscle cancer	0.00262	0.00267	CcSEcCtD
Lurasidone—Vision blurred—Methotrexate—muscle cancer	0.00256	0.00261	CcSEcCtD
Lurasidone—Diarrhoea—Etoposide—muscle cancer	0.00253	0.00258	CcSEcCtD
Lurasidone—Eye disorder—Doxorubicin—muscle cancer	0.00252	0.00257	CcSEcCtD
Lurasidone—Anaemia—Methotrexate—muscle cancer	0.00251	0.00256	CcSEcCtD
Lurasidone—Cardiac disorder—Doxorubicin—muscle cancer	0.00251	0.00256	CcSEcCtD
Lurasidone—Angiopathy—Doxorubicin—muscle cancer	0.00245	0.0025	CcSEcCtD
Lurasidone—Malaise—Methotrexate—muscle cancer	0.00245	0.0025	CcSEcCtD
Lurasidone—Dizziness—Etoposide—muscle cancer	0.00245	0.00249	CcSEcCtD
Lurasidone—Vertigo—Methotrexate—muscle cancer	0.00244	0.00249	CcSEcCtD
Lurasidone—Leukopenia—Methotrexate—muscle cancer	0.00243	0.00248	CcSEcCtD
Lurasidone—Arrhythmia—Doxorubicin—muscle cancer	0.00241	0.00246	CcSEcCtD
Lurasidone—HTR2A—hindlimb—muscle cancer	0.00241	0.121	CbGeAlD
Lurasidone—Mental disorder—Doxorubicin—muscle cancer	0.00236	0.00241	CcSEcCtD
Lurasidone—Convulsion—Methotrexate—muscle cancer	0.00235	0.0024	CcSEcCtD
Lurasidone—Vomiting—Etoposide—muscle cancer	0.00235	0.0024	CcSEcCtD
Lurasidone—Malnutrition—Doxorubicin—muscle cancer	0.00235	0.0024	CcSEcCtD
Lurasidone—Rash—Etoposide—muscle cancer	0.00233	0.00238	CcSEcCtD
Lurasidone—Dermatitis—Etoposide—muscle cancer	0.00233	0.00238	CcSEcCtD
Lurasidone—Flatulence—Doxorubicin—muscle cancer	0.00232	0.00236	CcSEcCtD
Lurasidone—Myalgia—Methotrexate—muscle cancer	0.00231	0.00236	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00229	0.00234	CcSEcCtD
Lurasidone—Back pain—Doxorubicin—muscle cancer	0.00227	0.00232	CcSEcCtD
Lurasidone—Muscle spasms—Doxorubicin—muscle cancer	0.00226	0.00231	CcSEcCtD
Lurasidone—Vision blurred—Doxorubicin—muscle cancer	0.00221	0.00226	CcSEcCtD
Lurasidone—Infection—Methotrexate—muscle cancer	0.0022	0.00225	CcSEcCtD
Lurasidone—Nausea—Etoposide—muscle cancer	0.0022	0.00224	CcSEcCtD
Lurasidone—Nervous system disorder—Methotrexate—muscle cancer	0.00217	0.00222	CcSEcCtD
Lurasidone—Anaemia—Doxorubicin—muscle cancer	0.00217	0.00222	CcSEcCtD
Lurasidone—Agitation—Doxorubicin—muscle cancer	0.00216	0.0022	CcSEcCtD
Lurasidone—Skin disorder—Methotrexate—muscle cancer	0.00215	0.0022	CcSEcCtD
Lurasidone—Hyperhidrosis—Methotrexate—muscle cancer	0.00214	0.00218	CcSEcCtD
Lurasidone—Malaise—Doxorubicin—muscle cancer	0.00212	0.00216	CcSEcCtD
Lurasidone—Vertigo—Doxorubicin—muscle cancer	0.00211	0.00215	CcSEcCtD
Lurasidone—Syncope—Doxorubicin—muscle cancer	0.00211	0.00215	CcSEcCtD
Lurasidone—Leukopenia—Doxorubicin—muscle cancer	0.0021	0.00215	CcSEcCtD
Lurasidone—Hypotension—Methotrexate—muscle cancer	0.00207	0.00211	CcSEcCtD
Lurasidone—HTR2A—appendage—muscle cancer	0.00207	0.103	CbGeAlD
Lurasidone—Loss of consciousness—Doxorubicin—muscle cancer	0.00207	0.00211	CcSEcCtD
Lurasidone—Convulsion—Doxorubicin—muscle cancer	0.00204	0.00208	CcSEcCtD
Lurasidone—Hypertension—Doxorubicin—muscle cancer	0.00203	0.00207	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.00202	0.00206	CcSEcCtD
Lurasidone—Insomnia—Methotrexate—muscle cancer	0.002	0.00204	CcSEcCtD
Lurasidone—Myalgia—Doxorubicin—muscle cancer	0.002	0.00204	CcSEcCtD
Lurasidone—Anxiety—Doxorubicin—muscle cancer	0.00199	0.00203	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00199	0.00203	CcSEcCtD
Lurasidone—Dyspnoea—Methotrexate—muscle cancer	0.00197	0.00201	CcSEcCtD
Lurasidone—Somnolence—Methotrexate—muscle cancer	0.00197	0.00201	CcSEcCtD
Lurasidone—Dry mouth—Doxorubicin—muscle cancer	0.00196	0.002	CcSEcCtD
Lurasidone—Dyspepsia—Methotrexate—muscle cancer	0.00195	0.00199	CcSEcCtD
Lurasidone—Decreased appetite—Methotrexate—muscle cancer	0.00193	0.00196	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00191	0.00195	CcSEcCtD
Lurasidone—Fatigue—Methotrexate—muscle cancer	0.00191	0.00195	CcSEcCtD
Lurasidone—Infection—Doxorubicin—muscle cancer	0.00191	0.00194	CcSEcCtD
Lurasidone—Shock—Doxorubicin—muscle cancer	0.00189	0.00193	CcSEcCtD
Lurasidone—Nervous system disorder—Doxorubicin—muscle cancer	0.00188	0.00192	CcSEcCtD
Lurasidone—Tachycardia—Doxorubicin—muscle cancer	0.00187	0.00191	CcSEcCtD
Lurasidone—Skin disorder—Doxorubicin—muscle cancer	0.00186	0.0019	CcSEcCtD
Lurasidone—Hyperhidrosis—Doxorubicin—muscle cancer	0.00185	0.00189	CcSEcCtD
Lurasidone—Gastrointestinal pain—Methotrexate—muscle cancer	0.00181	0.00185	CcSEcCtD
Lurasidone—Hypotension—Doxorubicin—muscle cancer	0.00179	0.00183	CcSEcCtD
Lurasidone—Abdominal pain—Methotrexate—muscle cancer	0.00175	0.00179	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00175	0.00178	CcSEcCtD
Lurasidone—Insomnia—Doxorubicin—muscle cancer	0.00173	0.00177	CcSEcCtD
Lurasidone—Dyspnoea—Doxorubicin—muscle cancer	0.00171	0.00174	CcSEcCtD
Lurasidone—Somnolence—Doxorubicin—muscle cancer	0.0017	0.00174	CcSEcCtD
Lurasidone—Dyspepsia—Doxorubicin—muscle cancer	0.00169	0.00172	CcSEcCtD
Lurasidone—Decreased appetite—Doxorubicin—muscle cancer	0.00167	0.0017	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.00166	0.00169	CcSEcCtD
Lurasidone—Fatigue—Doxorubicin—muscle cancer	0.00165	0.00169	CcSEcCtD
Lurasidone—Asthenia—Methotrexate—muscle cancer	0.00159	0.00162	CcSEcCtD
Lurasidone—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00157	0.0016	CcSEcCtD
Lurasidone—Pruritus—Methotrexate—muscle cancer	0.00157	0.0016	CcSEcCtD
Lurasidone—Abdominal pain—Doxorubicin—muscle cancer	0.00152	0.00155	CcSEcCtD
Lurasidone—Diarrhoea—Methotrexate—muscle cancer	0.00152	0.00155	CcSEcCtD
Lurasidone—Dizziness—Methotrexate—muscle cancer	0.00146	0.00149	CcSEcCtD
Lurasidone—Vomiting—Methotrexate—muscle cancer	0.00141	0.00144	CcSEcCtD
Lurasidone—Rash—Methotrexate—muscle cancer	0.0014	0.00142	CcSEcCtD
Lurasidone—Dermatitis—Methotrexate—muscle cancer	0.0014	0.00142	CcSEcCtD
Lurasidone—Asthenia—Doxorubicin—muscle cancer	0.00138	0.0014	CcSEcCtD
Lurasidone—Pruritus—Doxorubicin—muscle cancer	0.00136	0.00138	CcSEcCtD
Lurasidone—Nausea—Methotrexate—muscle cancer	0.00132	0.00134	CcSEcCtD
Lurasidone—Diarrhoea—Doxorubicin—muscle cancer	0.00131	0.00134	CcSEcCtD
Lurasidone—Dizziness—Doxorubicin—muscle cancer	0.00127	0.00129	CcSEcCtD
Lurasidone—Vomiting—Doxorubicin—muscle cancer	0.00122	0.00124	CcSEcCtD
Lurasidone—Rash—Doxorubicin—muscle cancer	0.00121	0.00123	CcSEcCtD
Lurasidone—Dermatitis—Doxorubicin—muscle cancer	0.00121	0.00123	CcSEcCtD
Lurasidone—Nausea—Doxorubicin—muscle cancer	0.00114	0.00116	CcSEcCtD
Lurasidone—HTR1A—renal system—muscle cancer	0.000871	0.0436	CbGeAlD
Lurasidone—HTR7—smooth muscle tissue—muscle cancer	0.000865	0.0433	CbGeAlD
Lurasidone—HTR7—renal system—muscle cancer	0.000833	0.0417	CbGeAlD
Lurasidone—ADRA2C—renal system—muscle cancer	0.000765	0.0383	CbGeAlD
Lurasidone—HTR2A—embryo—muscle cancer	0.000686	0.0344	CbGeAlD
Lurasidone—ADRA2C—cardiac atrium—muscle cancer	0.000686	0.0343	CbGeAlD
Lurasidone—HTR7—tendon—muscle cancer	0.00065	0.0325	CbGeAlD
Lurasidone—ADRA2C—tendon—muscle cancer	0.000597	0.0299	CbGeAlD
Lurasidone—HTR1A—head—muscle cancer	0.000583	0.0292	CbGeAlD
Lurasidone—HTR7—head—muscle cancer	0.000557	0.0279	CbGeAlD
Lurasidone—ADRA2C—vagina—muscle cancer	0.000554	0.0278	CbGeAlD
Lurasidone—ADRA2A—cardiac atrium—muscle cancer	0.000547	0.0274	CbGeAlD
Lurasidone—HTR2A—smooth muscle tissue—muscle cancer	0.000539	0.027	CbGeAlD
Lurasidone—HTR7—testis—muscle cancer	0.000538	0.0269	CbGeAlD
Lurasidone—DRD2—head—muscle cancer	0.000527	0.0264	CbGeAlD
Lurasidone—HTR2A—renal system—muscle cancer	0.000519	0.026	CbGeAlD
Lurasidone—ADRA2C—head—muscle cancer	0.000512	0.0256	CbGeAlD
Lurasidone—DRD2—testis—muscle cancer	0.000509	0.0255	CbGeAlD
Lurasidone—ADRA2C—testis—muscle cancer	0.000495	0.0248	CbGeAlD
Lurasidone—CYP3A4—renal system—muscle cancer	0.000481	0.0241	CbGeAlD
Lurasidone—ADRA2A—tendon—muscle cancer	0.000477	0.0239	CbGeAlD
Lurasidone—ADRA2A—vagina—muscle cancer	0.000442	0.0221	CbGeAlD
Lurasidone—ADRA2A—head—muscle cancer	0.000409	0.0205	CbGeAlD
Lurasidone—HTR2A—tendon—muscle cancer	0.000405	0.0203	CbGeAlD
Lurasidone—ADRA2A—testis—muscle cancer	0.000395	0.0198	CbGeAlD
Lurasidone—HTR2A—vagina—muscle cancer	0.000376	0.0188	CbGeAlD
Lurasidone—HTR2A—head—muscle cancer	0.000347	0.0174	CbGeAlD
Lurasidone—HTR2A—testis—muscle cancer	0.000336	0.0168	CbGeAlD
